This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
About the network
The Lung Cancer Policy Network brings together a range of lung cancer expertise including screening, patient organisations and industry partners. Our members contribute their time for free. The Network’s activities are led by its members, with all materials representing a consensus view of the experts contributing to the Network. All outputs produced by the Network are non-promotional.
The Network is funded by multiple organisations. Details of funding tiers are included in the Terms of Reference.
Read the full Network Terms of Reference
The full Terms of Reference for the Network can be downloaded by clicking the button below. All Network members agree to the Terms of Reference, and any edits to the these are made by Network members’ consensus.
Read hereInterim Advisory Committee
The Network’s Secretariat currently works under the guidance of an Interim Advisory Committee. The Interim Advisory Committee is made up of Lung Ambition Alliance (LAA) founding partners, in addition to Funders of the Network.
At the end of 2022, we will establish a formal Network Steering Committee made up of seven members of the Network, through a process of member election.
Current members of the Interim Advisory Committee:
- Benjamin Gannon, Guardant Health
- Jennifer Higgins, Guardant Health
- Lucy Dance, AstraZeneca
- Caius Kim, AstraZeneca
- Helen Haggart, Johnson & Johnson
- Becky Bunn, International Association for the Study of Lung Cancer (IASLC)
- Murry Wynes, IASLC
- Carolyn ‘Bo’ Aldigé, Prevent Cancer Foundation
- Matz Fredriksson, Medtronic
- Ghenwa Kambris, Medtronic
How the Network is funded
The Network is funded by multiple organisations. Details of funding tiers are included in the Terms of Reference.
Major Funders
- AstraZeneca
- Guardant Health
- Johnson & Johnson
Minor Funders
- Medtronic
Partners of the Lung Ambition Alliance
- The International Association for the Study of Lung Cancer (IASLC)
- The Global Lung Cancer Coalition (GLCC)
Funders and LAA partners
Secretariat
The Secretariat for the Network is provided by The Health Policy Partnership (HPP), an independent health policy organisation. HPP coordinates and delivers all Network activities, engages Members and new Funders, and provides operational support for the Network.
Our work in 2022
The Network has two core work packages for 2022:
-
A report highlighting the lessons that have been learnt from lung cancer screening implementation.
-
An interactive map of lung cancer screening implementation research and organised programmes from around the globe.
